Sleep Med Psychophysiol.  1997 Dec;4(2):181-190.

Comparison of Effects of Zolpidem, Triazolam, and Placebo on the Insomnia of Schizophrenic Inpatients

  • 1Department of Psychiatry, College of Medicine, Gyeonsang National University, Gyeongsang Institute for Neuroscience.


Zolpidem is a relatively new, short-acting, rapid onset, and nonbenzodiazepine hypnotics. Zolpidem selectively binds to the central benzodiazepine 1 (BZI) receptor subtype. The present study was designed to compare the hypnotic effects of zolidem (10mg), triazolam (0.25mg), and placebo in 22 schizophrenic inpatients. Zopidem, triazoam, and placebo were administered orally in a randomized, double-blind design. Compared with placebo, zolpidem and triazolam significantly decreased sleep latency (p<0.05), increased total sleep time(p<0.05), and increased improvement of satisfaction of sleep(p<0.05). Zolpidem decreased the number of awakenings significantly in comparison with placebo(p<0.05),but trialzolam did not. In addition, both drugs were well tolerated and did not produce severe side effects. These results suggest that zolpidem is effective for transient insomnia of schizophrenic inpatients and zolpidem is superior to triazolam in hypnotic effect.


Insomnia; Schizophrenia; Zolpidem Triazolam
Full Text Links
  • SMP
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: